REG - Oxford Biomedica PLC - Oxford BioMedica Annual General Meeting <Origin Href="QuoteRef">OXB.L</Origin>

Oxford BioMedicaAnnouncement

07/06/2016 13:15

RNS Number : 4651A
Oxford Biomedica PLC
07 June 2016
Oxford BioMedica Annual General Meeting
London, UK - 7 June 2016: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.
In accordance with Listing Rule 9.6.18 the following resolutions are those which were passed at the meeting concerning special business:
 Resolution 9: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares; and
 Resolution 10: to permit the Group to convene general meetings (other than annual general meetings) on not less than 14 days' notice. 
The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Group's website at www.oxfordbiomedica.co.uk.
Certified copies of the document setting out the above resolutions passed at the 2016 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: http://www.morningstar.co.uk/uk/NSM.
The results of the proxy voting in advance of the meeting are shown below. On the Record Date (3 June 2016) there were 2,703,149,291 1p ordinary shares in issue, each carrying one vote per share.
Resolution
Votes
For
Votes at
Chairman's
Discretion
Votes at
other proxy
Discretion
Votes
Against
Votes
Withheld
Total
votes cast
Result








Ordinary resolutions













1
1,485,649,973
3,312,033
2,846,516
38,490
33,512
1,491,880,524
Passed








2
1,476,569,089
3,441,302
2,846,516
1,251,449
7,772,168
1,491,880,524
Passed








3
1,485,481,782
3,315,455
2,846,516
74,890
145,180
1,491,863,823
Passed
4
1,483,363,810
3,326,126
2,846,516
2,134,604
209,468
1,491,880,524
Passed








5
1,370,961,344
3,315,455
2,846,516
111,174,129
3,583,080
1,491,880,524
Passed








6
1,485,446,226
3,355,455
2,846,516
87,809
144,518
1,491,880,524
Passed








7
1,395,088,017
3,321,608
2,846,516
87,748,985
2,875,398
1,491,880,524
Passed








8
1,485,136,315
3,389,372
2,846,516
443,395
64,926
1,491,880,524
Passed
















Special resolutions













9
1,484,857,700
3,403,028
2,846,516
663,953
109,327
1,491,880,524
Passed








10
1,483,284,959
3,449,017
2,846,516
2,194,336
105,696
1,491,880,524
Passed








- Ends -
For further information, please contact:
Oxford BioMedica plc:
John Dawson, Chief Executive Officer
Tim Watts, Chief Financial Officer
Tel: +44 (0)1865 783 000
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton
Tel: +44 (0)20 3709 5700
Notes for editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 230 people. Further information is available at www.oxfordbiomedica.co.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RAGEAAKXEFDKEFF